WO2001019376A3 - METHOD OF INHIBITING NF-λB WITH HEPARIN, FOR TREATING CARDIOVASCULAR DISEASES AND INFLAMMATIONS - Google Patents
METHOD OF INHIBITING NF-λB WITH HEPARIN, FOR TREATING CARDIOVASCULAR DISEASES AND INFLAMMATIONS Download PDFInfo
- Publication number
- WO2001019376A3 WO2001019376A3 PCT/US2000/024910 US0024910W WO0119376A3 WO 2001019376 A3 WO2001019376 A3 WO 2001019376A3 US 0024910 W US0024910 W US 0024910W WO 0119376 A3 WO0119376 A3 WO 0119376A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heparin
- inflammations
- inhibiting
- cardiovascular diseases
- treating cardiovascular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU73701/00A AU763042B2 (en) | 1999-09-13 | 2000-09-12 | Method of inhibiting NF-kappaB with heparin |
EP00961798A EP1223948A2 (en) | 1999-09-13 | 2000-09-12 | Method of inhibiting nf-kappa-b with heparin, for treating cardiovascular diseases and inflammations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39508199A | 1999-09-13 | 1999-09-13 | |
US09/395,081 | 1999-09-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001019376A2 WO2001019376A2 (en) | 2001-03-22 |
WO2001019376A3 true WO2001019376A3 (en) | 2001-12-13 |
Family
ID=23561619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/024910 WO2001019376A2 (en) | 1999-09-13 | 2000-09-12 | METHOD OF INHIBITING NF-λB WITH HEPARIN, FOR TREATING CARDIOVASCULAR DISEASES AND INFLAMMATIONS |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1223948A2 (en) |
AU (1) | AU763042B2 (en) |
WO (1) | WO2001019376A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6489311B1 (en) * | 2000-05-02 | 2002-12-03 | Charlotte-Mecklenburg Hospital Authoirty | Method for the prevention of apoptosis |
US7468358B2 (en) | 2004-06-16 | 2008-12-23 | Paringenix, Inc. | Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome |
US20050282775A1 (en) * | 2004-06-16 | 2005-12-22 | Paringenix, Inc. | Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome |
US20060040896A1 (en) * | 2004-08-18 | 2006-02-23 | Paringenix, Inc. | Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity |
CA2694189A1 (en) * | 2007-07-23 | 2009-01-29 | University Of Utah Research Foundation | Method for blocking ligation of the receptor for advanced glycation end-products (rage) |
EP3785720A1 (en) | 2012-05-09 | 2021-03-03 | Cantex Pharmaceuticals, Inc. | Treatment of myelosuppression |
GB201219696D0 (en) | 2012-11-01 | 2012-12-12 | Univ Liverpool | Agents for the prevention and/or treatment of central nervous system damamge |
US20170096549A1 (en) | 2014-03-17 | 2017-04-06 | Cantex Pharmaceuticals, Inc. | Multivalent cation formulations of partially desulfated heparins |
EP3258941A4 (en) | 2015-02-17 | 2018-09-26 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0583865A1 (en) * | 1992-08-17 | 1994-02-23 | Transcend Therapeutics, Inc. | Prevention and treatment of atherosclerosis |
WO1998035691A1 (en) * | 1997-02-15 | 1998-08-20 | Proscript, Inc. | Treatment of infarcts through inhibition of nf-kappab |
-
2000
- 2000-09-12 AU AU73701/00A patent/AU763042B2/en not_active Ceased
- 2000-09-12 EP EP00961798A patent/EP1223948A2/en not_active Ceased
- 2000-09-12 WO PCT/US2000/024910 patent/WO2001019376A2/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0583865A1 (en) * | 1992-08-17 | 1994-02-23 | Transcend Therapeutics, Inc. | Prevention and treatment of atherosclerosis |
WO1998035691A1 (en) * | 1997-02-15 | 1998-08-20 | Proscript, Inc. | Treatment of infarcts through inhibition of nf-kappab |
Non-Patent Citations (9)
Title |
---|
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; June 1998 (1998-06-01), ZHAI GUANG-XI ET AL: "Preparation of low molecular weight heparin liposomal spray gel.", XP002165292, Database accession no. PREV199900005848 * |
FRYER ALLISON ET AL: "Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung.", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 282, no. 1, 1997, pages 208 - 219, XP000997372, ISSN: 0022-3565 * |
JORNESKOG GUN ET AL: "Low molecular weight heparin seems to improve local capillary circulation and healing of chronic foot ulcers in diabetic patients.", VASA, vol. 22, no. 2, 1993, pages 137 - 142, XP000997375, ISSN: 0301-1526 * |
KLEIMAN NEAL S ET AL: "Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: Evidence for a complex interaction in a multicenter trial.", CIRCULATION, vol. 97, no. 19, 19 May 1998 (1998-05-19), pages 1912 - 1920, XP000997371, ISSN: 0009-7322 * |
SACHE E ET AL: "PARTIALLY N DESULFATED HEPARIN AS A NON-ANTICOAGULANT HEPARIN SOME PHYSICO-CHEMICAL AND BIOLOGICAL PROPERTIES", THROMBOSIS RESEARCH, vol. 55, no. 2, 1989, pages 247 - 258, XP000997333, ISSN: 0049-3848 * |
TAKAZAKURA E ET AL: "A NEW THERAPEUTIC METHOD OF DIABETIC GANGRENE RESULTS IN 10 CASES WITH CONTINUOUS INTRA-ARTERIAL INFUSION OF PROSTAGLANDIN E-1 INSULIN AND HEPARIN", DIABETES RESEARCH AND CLINICAL PRACTICE, no. SUPPL. 1, 1985, pages S545 - S546, XP000997398, ISSN: 0168-8227 * |
THOURANI VINOD H ET AL: "Nonanticoagulant heparin inhibits NF-kappaB activation and attenuates myocardial reperfusion injury.", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 278, no. 6 Part 2, June 2000 (2000-06-01), pages H2084 - H2093, XP000997340, ISSN: 0002-9513 * |
VAN DER PIJL JOHAN W ET AL: "Effect of danaparoid sodium on hard exudates in diabetic retinopathy.", LANCET (NORTH AMERICAN EDITION), vol. 350, no. 9093, 13 December 1997 (1997-12-13), pages 1743 - 1745, XP000990739, ISSN: 0099-5355 * |
ZHONGGUO YIYAO GONGYE ZAZHI, vol. 29, no. 6, June 1998 (1998-06-01), pages 261 - 265, ISSN: 1001-8255 * |
Also Published As
Publication number | Publication date |
---|---|
EP1223948A2 (en) | 2002-07-24 |
AU763042B2 (en) | 2003-07-10 |
WO2001019376A2 (en) | 2001-03-22 |
AU7370100A (en) | 2001-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Agarwal | Supervised atenolol therapy in the management of hemodialysis hypertension | |
WO2002060389A3 (en) | Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same | |
WO2001012122A3 (en) | Method and system for treating cardiac arrest using hypothermia | |
WO2001089554A3 (en) | Treatment of acute coronary syndrome with glp-1 | |
SE9702860L (en) | Use of a strain of Lactobacillus for the manufacture of a drug for reducing fibrinogen content in blood | |
HUP9800467A2 (en) | Use of hyaluronic acid for producing pharmaceutical compns. for the treatment of interstitial cystitis | |
WO2001028491A3 (en) | Method and composition for the treatment of dermatologic diseases | |
WO2000021548A3 (en) | Angiogenically effective unit dose of fgf and method of administering | |
EP1733734A3 (en) | Placental alkaline phosphatase to control diabetes | |
WO2001019376A3 (en) | METHOD OF INHIBITING NF-λB WITH HEPARIN, FOR TREATING CARDIOVASCULAR DISEASES AND INFLAMMATIONS | |
AU4199197A (en) | A bandage for fixating a cannula of a venous catheter to a skin surface part f a person | |
EP1304108A3 (en) | Anti-arrhythmic composition and methods of treatment | |
WO2001012214A3 (en) | MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a) | |
GB9917405D0 (en) | Methods of treatment and drug screening methods | |
WO2001091785A3 (en) | Use of hyaluronidase for preventing and treating cardio vascular diseases | |
WO2002056837A3 (en) | Inhibition of protein-phosphatases for the treatment of heart failure | |
WO2001042205A3 (en) | Treatment of inflammatory bowel disease with vitamin d compounds | |
NZ513087A (en) | Bactericidal/permability -increasing protein (BPI) for treating chronic heart disease | |
CN2339238Y (en) | Cornoary artery sinus catheter | |
ZHUO et al. | Comparison of incidence, mortality and treatment of acute myocardial infarction in hospitals in Japan and China | |
WO2001019359A3 (en) | Medicaments containing pantothenic acid for the treatment of inflammatory joint disease | |
WO2005097102A3 (en) | Method to treat chronic heart failure and/or elevated cholesterol levels | |
Massetani et al. | Dream recall and dream content in levodopa-treated Parkinsonian patients. | |
Neutel et al. | P-373: A comparison of the effects of amlodipine 5 mg/benazepril 20 mg combination therapy to component monotherapy on arterial distensibilitly and left ventricular hypertrophy in patients with mild to moderate hypertension | |
Agishi | H. NAKAHAMA, ¹ T. NAKANISHI, ¹ O. UYAMA, ¹ M. SUGITA, ¹ M. MIYAZAKI, 2 N. IMAI, 2 T. YOKOKAWA, 2 M. OKADA¹ and S. KUBORI¹ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 73701/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000961798 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000961798 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 73701/00 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWR | Wipo information: refused in national office |
Ref document number: 2000961798 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000961798 Country of ref document: EP |